I-Mab to Rebrand as NovaBridge Biosciences, Eyes Hong Kong IPO

MT Newswires Live

Yesterday

I-Mab (IMAB) plans to become a global biotech platform focused on business development and translational clinical development under the new name NovaBridge Biosciences, with intentions for an initial public offering in Hong Kong as part of a dual listing with Nasdaq.

As part of its strategic pivot, I-Mab plans to acquire VIS-101, a bifunctional biologic for wet age-related macular degeneration and diabetic macular edema, via its new Visara subsidiary with Phase 3 readiness expected in 2026. Financial details weren't disclosed.

Additionally, Kyler Lei was appointed as chief financial officer, the company said Thursday in a statement.

The name change will take effect following expected approval at a shareholder meeting on Oct. 24, I-Mab said.

The company also reaffirmed previously announced givastomig investment plans as part of its new strategy.

I-Mab shares rose 1.7% in after-hours trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2576798407"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576798407\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576798407?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-17 05:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576798407","market":"us","top_or_hot":-1,"title":"I-Mab to Rebrand as NovaBridge Biosciences, Eyes Hong Kong IPO","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/IMAB\">I-Mab</a> (IMAB) plans to become a global biotech platform focused on business development and translational clinical development under the new name NovaBridge Biosciences, with intentions for an initial public offering in Hong Kong as part of a dual listing with Nasdaq.</p><p>As part of its strategic pivot, I-Mab plans to acquire VIS-101, a bifunctional biologic for wet age-related macular degeneration and diabetic macular edema, via its new Visara subsidiary with Phase 3 readiness expected in 2026. Financial details weren't disclosed.</p><p>Additionally, Kyler Lei was appointed as chief financial officer, the company said Thursday in a statement.</p><p>The name change will take effect following expected approval at a shareholder meeting on Oct. 24, I-Mab said.</p><p>The company also reaffirmed previously announced givastomig investment plans as part of its new strategy.</p><p>I-Mab shares rose 1.7% in after-hours trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>I-Mab to Rebrand as NovaBridge Biosciences, Eyes Hong Kong IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nI-Mab to Rebrand as NovaBridge Biosciences, Eyes Hong Kong IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-17 05:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/IMAB\">I-Mab</a> (IMAB) plans to become a global biotech platform focused on business development and translational clinical development under the new name NovaBridge Biosciences, with intentions for an initial public offering in Hong Kong as part of a dual listing with Nasdaq.</p><p>As part of its strategic pivot, I-Mab plans to acquire VIS-101, a bifunctional biologic for wet age-related macular degeneration and diabetic macular edema, via its new Visara subsidiary with Phase 3 readiness expected in 2026. Financial details weren't disclosed.</p><p>Additionally, Kyler Lei was appointed as chief financial officer, the company said Thursday in a statement.</p><p>The name change will take effect following expected approval at a shareholder meeting on Oct. 24, I-Mab said.</p><p>The company also reaffirmed previously announced givastomig investment plans as part of its new strategy.</p><p>I-Mab shares rose 1.7% in after-hours trading.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴资本持仓","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2576798407","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576798407","pubTimestamp":1760650702,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"I-Mab (IMAB) plans to become a global biotech platform focused on business development and translational clinical development under the new name NovaBridge Biosciences, with intentions for an initial ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","IMAB":"I-Mab","BK4139":"生物科技","BK4535":"淡马锡持仓","BK4526":"热门中概股"},"translate_title":"天境生物将更名为NovaBridge Biosciences，着眼于香港IPO","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMAB":1},"content_text":"I-Mab (IMAB) plans to become a global biotech platform focused on business development and translational clinical development under the new name NovaBridge Biosciences, with intentions for an initial public offering in Hong Kong as part of a dual listing with Nasdaq.As part of its strategic pivot, I-Mab plans to acquire VIS-101, a bifunctional biologic for wet age-related macular degeneration and diabetic macular edema, via its new Visara subsidiary with Phase 3 readiness expected in 2026. Financial details weren't disclosed.Additionally, Kyler Lei was appointed as chief financial officer, the company said Thursday in a statement.The name change will take effect following expected approval at a shareholder meeting on Oct. 24, I-Mab said.The company also reaffirmed previously announced givastomig investment plans as part of its new strategy.I-Mab shares rose 1.7% in after-hours trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}